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Abstract
Objective: To identify the prognostic biomarker candidates for stratification and 
long‐term surveillance of oral leukoplakia progressing to cancer via a systematic lit‐
erature review.
Materials and Methods: Systematic searches with no date restrictions were con‐
ducted on March 29, 2018, targeting the databases PubMed (Ovid), EMBASE (Ovid), 
EBM (Ovid), and Web of Science (ISI). Bias was assessed using the Quality in Prognosis 
Studies tool. Biomarkers were stratified based on hallmarks of cancer.
Results: Inclusion criteria were met by 25 of 3,415 studies. A range of biomarkers 
were evaluated experimentally for risk stratification, prognosis, and surveillance of 
oral leukoplakia in tissue, blood, and saliva. However, the studies were highly hetero‐
geneous and require further validation. Biomarkers reported in these studies in‐
cluded inflammatory or oxidative markers, growth factors, ion channels, genetic and 
cellular regulatory factors, and epigenetic biomarkers. Studies tended to include 
small sample sizes, under‐reported or variably reported histopathological data, did 
not address potential confounding, reported limited/variable follow‐up data, or 
lacked a control group. Inclusion of subsets from chemoprevention trials may have 
introduced bias regarding reported malignant transformation rates and accuracy of 
prognostic biomarkers.
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1  | INTRODUC TION
Oral squamous cell carcinoma (OSCC) continues to have significant 
clinical and economic impact at the international level. It is associ‐
ated with a high rate of mortality, which often is a consequence of 
delayed diagnosis due to lack of screening programs, low health lit‐
eracy relative to OSCC, and lack of access to care. The World Health 
Organization (WHO) projected 354,864 new cases of oral cavity and 
lip cancer in 2018 (Bray et al., 2018).
Oral potentially malignant disorders (OPMDs), of which leuko‐
plakia is one of the several phenotypes, represent a group of con‐
ditions and lesions with variable propensity for oncogenic potential 
(Warnakulasuriya, Johnson, & van der Waal, 2007). In the era of pre‐
cision medicine, there is burgeoning interest in defining and char‐
acterizing relative risk of oral cancer emergence in association with 
OPMD. As the understanding of the molecular pathogenesis of oral 
cancer continues to expand, there is active interest in identifying 
biomarkers that could provide ability for clinicians to longitudinally 
track key molecular signals associated with OPMD, and intervene 
prior to neoplastic transformation. The overarching aims of the 
systematic reviews performed by the Precision Medicine Group of 
World Workshop on Oral Medicine VII were to:
• Assess whether prognostic biomarkers could accurately stratify 
the risk of malignant transformation of oral leukoplakia.
• Assess the relationship between prognostic biomarkers and the 
patient's risk profile including lesion clinicopathologic character‐
istics in addition to patient's risk factors.
• Evaluate whether biomarkers could independently predict malig‐
nant transformation of oral leukoplakia.
• Establish the minimum follow‐up intervals required for biomark‐
ers to predict malignant transformation.
• Assess the efficacy of the investigated biomarkers and manage‐
ment protocol.
• Formulate an algorithm that would help clinicians to provide the 
best supported evidence‐based management protocol to patients 
with oral leukoplakia.
After oral submucous fibrosis, oral leukoplakia is the most 
common OPMD, with a worldwide prevalence of 4.11% (95% CI: 
1.98–6.97) (Mello et al., 2018). Leukoplakia has been defined by the 
WHO as “a white plaque of questionable risk having excluded (other) 
known diseases or disorders that carry no increased risk for cancer” 
(Warnakulasuriya et al., 2007). Risk factors for oral leukoplakia are 
similar to those observed in oral cancer and include tobacco smoking, 
heavy alcohol consumption, areca nut chewing (especially in South 
Asian countries), immunosuppression (e.g., HIV/AIDS, post‐organ 
transplantation), personal or family history of cancer (60%–70%), ultra‐
violet light exposure (for lip lesions only), and selected syndromes (e.g., 
dyskeratosis congenita) (Villa & Woo, 2017; Warnakulasuriya, 2018).
Leukoplakia is a clinical diagnosis, most commonly presenting 
in two main phenotypes: homogeneous and non‐homogeneous leu‐
koplakia. Proliferative verrucous leukoplakia represents a third, rarer, 
high‐risk subtype (Warnakulasuriya, 2018). Irrespective of type of 
oral leukoplakia, the gold standard for final diagnosis remains in‐
cisional biopsy. Risk of malignant transformation depends on the 
clinical form and the grade of dysplasia, although other clinical 
and histopathological parameters have been reported as drivers 
(Speight, Khurram, & Kujan, 2018). Non‐homogeneous leukoplakias 
carry a 20%–25% risk of cancer progression versus 0.6%–5% in ho‐
mogeneous cases (Napier & Speight, 2008; Reibel, 2003; van der 
Waal & Axell, 2002).
A key step to better understanding oral leukoplakia outcomes is 
to identify the molecular factors that drive malignant progression, 
as these factors may also represent attractive candidates for tar‐
geted therapies. With the advent of precision medicine, a growing 
evidence base has explored predictive and prognostic biomarkers 
for oral leukoplakia. This paper systematically reviewed longitudinal 
studies which specifically aimed to: (a) assess whether prognostic 
biomarkers could accurately stratify the risk of progression of oral 
leukoplakia to cancer, and (b) evaluate the reliability of biomarkers in 
long‐term surveillance of oral leukoplakia. Future studies will focus 
on the other overarching aims as mentioned above.
2  | MATERIAL S AND METHODS
This study was conducted by the Precision Medicine Work Group 
within the World Workshop on Oral Medicine VII (WWOM VII). 
Results are reported according to the Preferred Reporting Items for 
Systematic Reviews and Meta‐Analyses (PRISMA) statement (Moher, 
Liberati, Tetzlaff, & Altman, 2009). PICO (Patients, Intervention/
exposure/prognostic factor, Comparison group and Outcome) was 
used to formulate the research question.
• Patients: patients with oral leukoplakia
• Intervention/exposure/prognostic factor: biomarkers in human 
specimens (saliva, blood, gingival crevicular fluid, oral tissues)
Conclusions: This review identified insufficient longitudinal evidence to support vali‐
dated prognostic biomarkers for oral leukoplakia. Further studies are needed to iden‐
tify molecular targets with the potential to mitigate risk of malignant transformation.
K E Y W O R D S
biomarkers, cancer progression, leukoplakia, neoplastic cell transformation, prognosis, tumor
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• Comparison: healthy controls or patients with oral squamous cell 
carcinoma
• Outcome: squamous cell carcinoma
• Studies: longitudinal (prospective) studies
2.1 | Study selection
Studies that were potentially eligible for inclusion evaluated bio‐
marker expression in: (a) human specimens (saliva, blood, gingival 
crevicular fluid, oral tissues) with follow‐up data (over time); (b) 
patients with oral leukoplakia compared to healthy controls; or 
(c) patients with oral leukoplakia compared to patients with oral 
squamous cell carcinoma. Studies were excluded if they were: 
(a) studies investigating only non‐human tissues, (b) withdrawn/
retracted studies, (c) reviews, (d) case reports, (e) commentar‐
ies, (f) opinion articles, (g) letters to the Editor, or (h) congress 
abstracts.
The selection of studies for review was conducted in the follow‐
ing five steps as illustrated in Figure 1.
Step 1: Electronic literature searches were conducted on March 
29, 2018, using the PubMed (Ovid), EMBASE (Ovid), Evidence Based 
Medicine (EBM) Reviews (Ovid), and Web of Science (ISI) databases 
with no publication year restrictions. The search strategies accord‐
ing to the syntax rules of each database are displayed in Supporting 
Information Table S1. The identified citations were imported into the 
electronic database EndNote X8 (Clarivate Analytics, Philadelphia, 
PA, USA). Deduplication was achieved by the EndNote software and 
manually by the two reviewers (AVil and AC).
Each subsequent step was conducted by two blinded review‐
ers (AVil and AC) to exclude records ineligible for inclusion, based 
on sequential review of title only, title and abstract, and finally full 
text (Step 4). The applied exclusion categories are shown in Table 1. 
When more than one exclusion category would pertain to a study, 
the most important was selected. At each step, review discordance 
between the reviewers was resolved by discussion between the two 
reviewers (AVil and AC) under supervision of the senior reviewer 
(CSF).
Step 2: Among unique records screened by title, only 1,006 out 
of 3,145 were retained. Cohen's kappa statistic for inter‐reviewer 
agreement was 0.95 (95% CI: 0.94–0.96), and the absolute agree‐
ment between the two reviewers was 96.7%.
Step 3: Screening by both title and abstract resulted in reten‐
tion of 749 of 1,006 for full‐text review. The absolute agreement 
between the two reviewers was 96.7%, and the kappa statistic was 
0.92 (95% CI: 0.91–0.94).
Step 4: Based on review of the full text, 331 of 749 were re‐
tained based on identification of “leukoplakia” as the definitive 
diagnosis. The reasons for excluding the 418 studies are shown in 
Table 1.
Step 5: The remaining 331 papers were allocated to one or more 
of the following eligibility categories, which respectively assessed 
the efficacy of biomarkers in:
• Y1: stratifying the risk of progression of oral leukoplakia to cancer 
(prospective longitudinal studies only).
• Y2: long‐term surveillance of oral leukoplakia (longitudinal studies 
only).
F I G U R E  1   Selection of studies 
for systematic review of prognostic 
biomarkers for oral leukoplakia
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• Y3: diagnosis of oral leukoplakia as an adjunct to oral examination 
(prospective case–control/cross‐sectional studies only)
• Y4: progression of oral leukoplakia in a retrospective data set 
(case–control/cross‐sectional studies only)
• Y5: differentiating oral leukoplakia from controls; correlation of 
differential biomarker expression with diverse clinicopathologic 
parameters (case–control/cross‐sectional studies only).
Inter‐reviewer absolute agreement for Step 5 was 85.47%, and 
the kappa statistic was 0.59 (95% CI: 0.50–0.68), but 100% absolute 
agreement was reached upon a second revision.
As per title, the current report was limited to the 25 longitu‐
dinal studies included in the categories Y1 regarding progression 
risk and Y2 on long‐term surveillance. Consequently, 306 of 331 
studies classified by Y categories that did not meet eligibility for 
inclusion in Y1 or Y2 categories either due to lack of eligibility for 
any of the Y category or because they were included into cate‐
gories Y3–Y5 were excluded from further review in the current 
report. Of note, all papers included in the Y2 category were also 
included in the Y1 category and the results will therefore be re‐
ported collectively.
The reviewer (AVil) and the consultant (CSF) extracted and 
entered into specifically developed forms (Microsoft Excel 2010, 
Redmond, Washington, USA) all relevant data from the selected 
papers. Risk of bias for the 25 included studies was assessed in‐
dependently by one reviewer (AVil) and the consultant (CSF) using 
the “Quality in Prognosis Studies” (QUIPS) tool (Hayden, van der 
Windt, Cartwright, Cote, & Bombardier, 2013), which evaluates the 
six domains “study participation,” “study attrition,” “prognostic fac‐
tor measurement,” “outcome measurement,” “study confounding,” 
and “statistical analysis and reporting.” Discord was resolved by 
consensus.
2.2 | Statistical analysis
Absolute percent inter‐reviewer agreement and Cohen's kappa co‐
efficient were calculated using IBM Statistics 23 (SPSS, Chicago, 
Illinois, USA). The heterogeneity of the studies and the high number 
of different biomarkers studied prevented any quantitative analysis 
of the results, so no meta‐analysis was performed.
3  | RESULTS
Of the 331 publications eligible for the categories Y1–Y2 out of 
the originally identified 3,415 unique records, 25 studies were al‐
located to groups Y1 and Y2 and therefore included in this report 
(Figure 1). Results are reported by types of biomarkers stratified to 
the hallmarks of cancer (Hanahan & Weinberg, 2011). The main char‐
acteristics of the studies are presented in Table 2, and a detailed de‐
scription of the biomarkers identified is reported in the Supporting 
Information Appendix S1.
3.1 | Types of biomarkers
Biomarkers reported in these studies (Table 2) included inflam‐
matory or oxidative markers (Chang et al., 2013; Massarelli et al., 
2005; Rai, Kaur, Jacobs, & Singh, 2010), growth factors (Beenken 
et al., 1994, 1999; Uehara, Ikeda, Nonaka, & Asahina, 2010; Wan, 
Meyskens, Armstrong, Taylor, & Kennedy, 1999), cell signaling bio‐
markers (Saintigny et al., 2011, 2018, 2018; Sakata et al., 2017), 
genetic and cellular regulatory factors (Lee et al., 2000; Mao et al., 
1996; Nagao et al., 2017; Tanic, Tanic, Milasin, Vukadinovic, & 
Dimitrijevic, 2009; Visioli, Lauxen, Sant'ana Filho, & Rados, 2012), 
Exclusion category Reason for exclusion Number of studies
N0 Not English language 17
N1 Not original study (review, guideline, 
editorial, conference abstract)
2
N2 No human tissue or only immortalized 
human cell lines in vitro
3
N3 No clinical diagnosis of oral leukoplakia, only 
dysplasia
332
N4 Cancer patients only: resection margins/
perilesional tissue in oral/oropharynx 
squamous cell carcinoma; history of cancer 
prior to or during study; undergoing 
chemotherapy or radiation therapy
6
N5 Predatory journals 2
N6 Retracted articles, or title includes 
“expression of concern”
3
N7 Other reason for not meeting inclusion 
criteria
53
All (N1‐N7) Reports ineligible for inclusion 418
TA B L E  1   Reason for exclusion after 
full‐text assessment
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ion channels (Fernandez‐Valle, Rodrigo, Garcia‐Pedrero, et al., 2016; 
Fernandez‐Valle, Rodrigo, Rodriguez‐Santamarta, et al., 2016), sus‐
tained angiogenesis factors (Kawaguchi et al., 2008; Lin et al., 2010; 
Nayak et al., 2015; Saintigny et al., 2009; Yang et al., 2014), and epi‐
genetic biomarkers (Foy et al., 2015; Xiao et al., 2012; Yang et al., 
2013). Studies tended to include small sample sizes, under‐reported 
or variably reported histopathological data, did not address poten‐
tial confounding, reported limited/variable follow‐up data, or lacked 
a control group. Notably, 14 of the 25 studies were components 
of chemoprevention trials (Beenken et al., 1994; Foy et al., 2015; 
Kawaguchi et al., 2008; Lee et al., 2000; Mao et al., 1996; Massarelli 
et al., 2005; Nagao et al., 2017; Rai et al., 2010; Saintigny et al., 
2009, 2011, 2018; Uehara et al., 2010; Wan et al., 1999; Yang et al., 
2013). Inclusion of subsets from chemoprevention trials may have 
introduced bias regarding reported malignant transformation rates 
and accuracy of prognostic biomarkers.
3.2 | Quality assessment of the studies
Low risk of bias was observed in “statistical reporting,” “study partic‐
ipation,” “study attrition,” and “outcome measurement” (81%, 70%, 
52%, and 52% of included studies, respectively), while moderate 
risk of bias in “study confounding” was found in 70% of studies and 
in “outcome measurement,” “prognostic factor measurement,” and 
“study attrition” in 48% of the studies. Percentage of studies with 
high risk of bias was relatively low and varied between 0% and 11% 
across the different domains (Figure 2; Table 3).
4  | DISCUSSION
This systematic review was directed to identification of biomarkers 
that could predict the likelihood of malignant progression over time 
in patients affected by oral leukoplakia (Table 4). Therefore, only 
studies applying longitudinal designs were included. Overall, the 25 
included studies documented a wide range of biomarkers derived 
from three different anatomic sources: serum, tissue, and saliva. 
Heterogeneity of biomarkers investigated across these studies pre‐
cluded direct interstudy comparison in virtually all cases.
Whereas selected biomarkers that were examined longitudinally 
seem promising, major limitations delineated in the current studies 
prevent definitive clinical application at this time. Most of the stud‐
ies: (a) included small sample sizes with the largest comprising only 
162 patients (Kawaguchi et al., 2008); (b) suffered from a paucity of 
histopathological data for leukoplakia and a lack of reporting of de‐
mographics and potentially confounding factors such as age, tobacco 
smoking, and alcohol consumption (Table 2); (c) reported on limited 
and variable follow‐up data and/or did not include a control group. 
As such, no negative or positive predictive value was reported for 
the biomarkers. Each study included in the review evaluated distinct 
biomarkers, with the exception of podoplanin that was evaluated by 
two research groups (Kawaguchi et al., 2008; Saintigny et al., 2009), 
but continues to require further investigation. Thus, potential va‐
lidity of biomarkers examined to date remains to be demonstrated 
in other studies. Several included papers reported on biomarkers 
examined in the context of chemoprevention trials (14/25 studies) 
where intervention may have potentially impacted the malignant 
transformation rates and accuracy of prognostic biomarkers rela‐
tive to risk detection for malignant progression of oral leukoplakia 
(Beenken et al., 1994; Foy et al., 2015; Kawaguchi et al., 2008; Lee 
et al., 2000; Mao et al., 1996; Massarelli et al., 2005; Nagao et al., 
2017; Rai et al., 2010; Saintigny et al., 2009, 2011, 2018; Uehara 
et al., 2010; Wan et al., 1999; Yang et al., 2013). Finally, most studies 
exhibited a moderate risk of bias in association with missing data, 
no consideration of potential confounding, and availability of lim‐
ited follow‐up data (Table 3). Future studies should include a longer 
follow‐up (the longest one reported in the studies included for this 
systematic review was 7.5 years; by Saintigny et al., 2009) to capture 
all cases of oral leukoplakia that undergo malignant transformation. 
This requires a larger effort with multiple centers and resources 
involved. Notably, biomarker assessment was not conducted in a 
blinded manner in any of the included studies, further introducing 
additional potential for bias.
Ten studies aimed to identify objectively measured molecular 
biomarkers for potential utility in identifying patients with oral leu‐
koplakia at higher risk of malignant transformation. The remaining 14 
studies that incorporated biomarker assessment as part of chemo‐
prevention trials had other objectives. We defined the potential role 
of each of the biomarkers reported in these studies based on their 
relational juxtaposition to essential hallmarks of cancer (Hanahan & 
Weinberg, 2011).
Based on evidence available to date, candidate biomarkers for 
cancer progression in patients affected by leukoplakia examined in 
this systematic review lacked substantive evidence as harbingers of 
risk for malignant transformation of oral leukoplakia. However, we 
only included those studies that specifically described “leukoplakia”; 
studies that described dysplasia only were excluded. Consequently, 
some biomarkers with prognostic value for oral dysplastic lesions 
(and possibly some leukoplakia cases) may have been missed. In ad‐
dition, some of these biomarkers were captured in the Y3, Y4, or Y5 
F I G U R E  2   Risk of bias in the 25 included studies according to 
the Quality in Prognosis Studies (QUIPS) criteria (Hayden et al., 
2013)
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categories and will be reviewed separately in future publications by 
our group. One example of such a biomarker comes from the study by 
Zhang and colleagues who examined 296 oral premalignant lesions 
and showed that LOH at 3p and/or 9p was present in 20% of cases 
that underwent malignant transformation (Zhang et al., 2012), fur‐
ther supporting the role of LOH in malignant transformation of oral 
leukoplakia. Although LOH may indeed be a predictive biomarker 
for malignant transformation, this systematic review highlights that 
both clinical and histopathological descriptors of lesions should be 
included in future studies on the topic to ensure robustness of data, 
but also to allow subsequent meta‐analyses should more than one 
study investigate the same marker or set of markers.
This systematic review disclosed that insufficient longitudinal 
evidence is currently available to support identification of biomark‐
ers that could improve current methods for detection of leukoplakia 
and any subsequent malignant disease progression. Therefore, the 
strength of the current evidence precludes advancement of any can‐
didate biomarkers examined to date into clinical practice. While a 
variety of technologies and laboratory techniques were employed 
to measure biomarker expression (including IHC, PCR, ELISA, and 
next‐generation sequencing), outcomes of these studies based on 
the current body of evidence do not achieve the standards required 
to identify and validate candidate biomarkers investigated to date. 
While recent advancements in biomarker development using mi‐
croarray technology, mass spectrometry, next‐generation sequenc‐
ing, and proteomic technologies have facilitated accomplishment of 
relatively rapid screening in real time, one of the major challenges 
that remain unaddressed is the validation in large longitudinal tri‐
als to assess the true effectiveness of these biomarkers. Reliable, 
sensitive, and specific biomarkers are needed to predict malignant 
transformation in patients affected by leukoplakia and inform phy‐
sicians on correct treatment decisions. Thus, their relative value 
TA B L E  4   Biomarkers used with leukoplakia specimens in the 25 studies displayed in Table 2
Biomarker acronym Biomarker name and function
CP Chromosomal polysomy
CRP C‐reactive protein; acute inflammatory marker
E‐cadherin Molecule that makes cells adhere to each other (cadherin = “calcium‐dependent adhesion”)
eGFR, EGFR Epidermal growth factor receptor
E‐selectin Cell adhesion molecule only expressed on endothelial cells activated by cytokines; inflammatory marker
FGF Basic fibroblast growth factor and signaling protein
FGFR Fibroblast growth factor receptor
GDF Growth differentiation factor
GRP Glucose‐regulated protein
HER Human epidermal growth factor receptor
HERG Human ether‐à‐go‐go related gene
ICAM Intercellular adhesion molecule; inflammatory marker
IL Interleukin, cytokines (secreted proteins, signal molecules)
Ki‐67 Antigen, nuclear protein
Kv3.4 Potassium voltage‐gated channel gene
M‐CSF Macrophage colony‐stimulating factor; inflammatory marker
MET Mesenchymal–epithelial transition
MDA Malondialdehyde; oxidative marker
miRNA Micro‐ribonucleic acid
MMP Matrix metalloproteinase
MYC Family of regulator genes and proto‐oncogenes that code for transcription factors (MyC: Myelocytomatosis) 
ΔNp63 Tumor protein p63
8‐OHdG 8‐hydroxydeoxyguanosine
p21WAF1 Tumor protein, cell cycle protein regulators
p27 Protein that regulates the cell cycle
p53 Tumor protein, cell cycle protein regulators
Podoplanin Mucin‐type protein, specific lymphatic vessel marker
RAR‐β Retinoic acid receptor‐Beta
SAA Serum amyloid A; inflammatory marker
SMAD4 Mothers against decapentaplegic homolog 4 gene
TGF Transforming growth factor; inflammatory marker
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remains equivocal pending validation in future appropriately de‐
signed studies, with no advances currently observed. Well‐designed, 
randomized controlled studies with proper follow‐up are required to 
propose and validate biomarkers for the purpose of establishing a 
new basis for their clinical and diagnostic utility. Consequently, cli‐
nicians continue to rely on tissue biopsy and histopathological as‐
sessment of oral dysplasia as the gold standard to determine the risk 
of malignant transformation and management strategies for patients 
with oral leukoplakia.
Limitations in tissue availability of leukoplakia samples (often 
small, formalin‐fixed paraffin‐embedded) and the preinvasive nature 
of leukoplakia may limit its systemic detectable expression in saliva 
and blood. Two promising biomarkers identified in this systematic 
review included podoplanin and cell cycle regulators. Podoplanin 
was identified as a possible independent predictor for cancer pro‐
gression (hazard ratio = 3.1; 95% CI: 1.5–6.2) (Kawaguchi et al., 
2008), and p27 loss was shown to be an independent factor for ma‐
lignant transformation (p = 0.02) (Massarelli et al., 2005). However, 
despite the potential for greatly improving current clinical tools and 
collective recent advances, there is still insufficient longitudinal ev‐
idence to support the identification of these and other biomarkers 
that could improve the current methods for detection of leukopla‐
kia and any subsequent malignant disease progression based on the 
25 studies that met eligibility for inclusion in this systematic review. 
Thus, oral epithelial dysplasia on histopathological assessment of a 
biopsy specimen currently remains the best predictor for transfor‐
mation to invasive squamous cell carcinoma.
4.1 | Future directions
The past decade has seen an increase in availability and access to 
high‐throughput profiling and sequencing technologies for genomic 
analysis and increased bioinformatic approaches to support rapid 
and comprehensive investigations of multi‐omics data in the precan‐
cer and cancer research domain. The growing capacity for integra‐
tion and systems analysis of multi‐omics data needs to be pursued to 
help elucidate interactions between genetic and epigenetic altera‐
tions being recognized in leukoplakia and promote identification of a 
prognostic biomarker or panel of biomarkers with improved poten‐
tial for cancer prediction and simultaneously definition of pathways 
involved in malignant transformation including candidate molecules 
which could be targeted by therapeutic interventions to impede pro‐
gression of oral leukoplakia to invasive cancer. Notably, the era of 
precision medicine has seen achievement of this goal in the context 
of some cancers, including breast cancer. Achievement of this goal is 
further linked to definition of specific genetic alterations associated 
with leukoplakia and processes that drive malignant transforma‐
tion. Increased understanding of these processes will also promote 
further identification of candidate biomarkers that may represent 
detectable molecular signals arising as a consequence of transfor‐
mational processes. In the future, additional well‐designed research 
that defines triggers of leukoplakia progression through integrated, 
ad hoc computational analyses is needed to leverage genomic and 
other meta‐data in defining appropriate candidate biomarkers and 
tailored molecular targets with translational potential to mitigate 
risk of malignant transformation associated with leukoplakia.
As more high‐throughput technologies such as next‐generation 
sequencing are utilized in the discovery of diagnostic, prognostic, 
and predictive biomarkers, it is incumbent on researchers to better 
understand biomarker types and to better plan study designs to suit 
the biomarker type but also the question at hand. In the case of oral 
leukoplakia malignant transformation, assessing DNA tissue bio‐
markers through genome‐wide association studies or even exome 
sequencing in affected individuals may provide insight into genetic 
mutations or aberrations of susceptibility in affected individuals, 
and, if followed up over time, may lead to discovery of a suscepti‐
bility profile for malignant transformation, as it is known that not 
all leukoplakias progress to malignancy. These biomarkers can be 
tested retrospectively on biobanked samples, and would hasten bio‐
marker discovery as patient recruitment for biomarker study design 
would not necessarily need to proceed prospectively. DNA tumor 
biomarkers of oral leukoplakia samples themselves may offer equally 
interesting insights, but would require a prospective study design. 
These biomarkers would be amenable for testing therapy response 
and pharmacodynamics, but may suffer from lack of reproducibility 
as different somatic mutations may be present in different parts of 
the lesion, thus highlighting the importance of biopsy site selection 
and multiple sampling of oral leukoplakia. Nonetheless, having this 
insight would dramatically increase our ability to discuss treatment 
options with patients, and would be invaluable prognostic predictors 
for therapy. Finally, RNA, protein, or metabolite biomarkers can be 
assayed as DNA tumor biomarkers, but have the advantage of being 
tested in a variety of biosamples including blood, saliva, gingival 
crevicular fluid, tissue, or cell scrapes, would equally be amenable 
to therapy testing and monitoring of response, would provide repro‐
ducibility at any one point in time, and could be used in prospective 
study designs, but additionally would be suitable as surrogate mark‐
ers of disease. Furthermore, their discovery can elucidate molecular 
pathways involved in malignant transformation and provide more 
comprehensive insights into this process.
Ideally, collaborative research, at the international level, stra‐
tegically designed to systematically collect and analyze data is re‐
quired in order to (a) achieve a robust, adequately powered study 
population for follow‐up of patients with leukoplakia and (b) observe 
progression in a larger subset of patients than is normally possible 
in single‐center studies due to the relatively low rate of malignant 
transformation. Patients with newly diagnosed leukoplakia should 
be included with subsequent longitudinal follow‐up, and collection 
of structured data at specifically defined time points. Future studies 
should also focus on identifying biomarkers by integrating ‐omics 
data with environmental and lifestyle variables with the final goal 
of identifying more informative predictors of cancer progression 
that supersede dependence on histopathological diagnosis alone. 
Collection of these data into a centralized repository in the con‐
text of good histopathology data would further create a resource 
amenable to application of bioinformatic approaches and predictive 
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modeling to identify the most informative variables for screening 
across time.
5  | CONCLUSIONS
This review identified insufficient longitudinal evidence to support 
validated prognostic biomarkers for oral leukoplakia. Further stud‐
ies are needed to identify molecular targets with the potential to 
mitigate risk of malignant transformation of oral leukoplakia to ad‐
vance precision medicine approaches to management of patients 
with these lesions.
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